Item request has been placed!
×
Item request cannot be made.
×
Processing Request
SARS-CoV-2 intra-host diversity, antibody response, and disease severity after reinfection by the variant of concern Gamma in Brazil.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
- Publication Information:
Original Publication: London : Nature Publishing Group, copyright 2011-
- Subject Terms:
- Abstract:
The rapid spread of the SARS-CoV-2 Variant of Concern (VOC) Gamma in Amazonas during early 2021 fueled a second large COVID-19 epidemic wave and raised concern about the potential role of reinfections. Very few cases of reinfection associated with the VOC Gamma have been reported to date, and their potential impact on clinical, immunological, and virological parameters remains largely unexplored. Here we describe 25 cases of SARS-CoV-2 reinfection in Brazil. SARS-CoV-2 genomic analysis confirmed that individuals were primo-infected with distinct viral lineages between March and December 2020 (B.1.1, B.1.1.28, B.1.1.33, B.1.195, and P.2) and reinfected with the VOC Gamma between 3 to 12 months after primo-infection. We found a similar mean cycle threshold (Ct) value and limited intra-host viral diversity in both primo-infection and reinfection samples. Sera of 14 patients tested 10-75 days after reinfection displayed detectable neutralizing antibodies (NAb) titers against SARS-CoV-2 variants that circulated before (B.1.*), during (Gamma), and after (Delta and Omicron) the second epidemic wave in Brazil. All individuals had milder or no symptoms after reinfection, and none required hospitalization. These findings demonstrate that individuals reinfected with the VOC Gamma may display relatively high RNA viral loads at the upper respiratory tract after reinfection, thus contributing to onward viral transmissions. Despite this, our study points to a low overall risk of severe Gamma reinfections, supporting that the abrupt increase in hospital admissions and deaths observed in Amazonas and other Brazilian states during the Gamma wave was mostly driven by primary infections. Our findings also indicate that most individuals analyzed developed a high anti-SARS-CoV-2 NAb response after reinfection that may provide some protection against reinfection or disease by different SARS-CoV-2 variants.
(© 2023. The Author(s).)
- References:
PLoS Pathog. 2021 Apr 7;17(4):e1009499. (PMID: 33826681)
Cell Mol Immunol. 2021 Feb;18(2):318-327. (PMID: 33408342)
Microb Genom. 2022 Mar;8(3):. (PMID: 35297757)
Immunity. 2021 Oct 12;54(10):2172-2176. (PMID: 34626549)
JAMA Netw Open. 2022 Apr 1;5(4):e227650. (PMID: 35442459)
Clin Infect Dis. 2022 Feb 11;74(3):407-415. (PMID: 33972994)
Rev Inst Med Trop Sao Paulo. 2021 Apr 23;63:e36. (PMID: 33909850)
Cell Rep Med. 2021 Jun 15;2(6):100290. (PMID: 33969322)
Lancet Reg Health Eur. 2022 Sep;20:100453. (PMID: 35791336)
Microbiol Spectr. 2022 Feb 23;10(1):e0236621. (PMID: 35196783)
Science. 2021 Apr 16;372(6539):. (PMID: 33688063)
Lancet. 2022 Jun 25;399(10344):2326-2327. (PMID: 35405083)
Nat Methods. 2017 Jun;14(6):587-589. (PMID: 28481363)
Syst Biol. 2006 Aug;55(4):539-52. (PMID: 16785212)
Viruses. 2022 Jan 23;14(2):. (PMID: 35215811)
Bioinformatics. 2006 Jul 1;22(13):1658-9. (PMID: 16731699)
Lancet Microbe. 2021 Dec;2(12):e666-e675. (PMID: 34632431)
Mem Inst Oswaldo Cruz. 2020 Sep 25;115:e200310. (PMID: 32997001)
Clin Infect Dis. 2021 Nov 2;73(9):1745. (PMID: 34586376)
Indian J Med Res. 2020 Jul & Aug;152(1 & 2):82-87. (PMID: 32859866)
Front Public Health. 2022 May 02;10:884121. (PMID: 35586006)
PLoS Pathog. 2021 Aug 23;17(8):e1009849. (PMID: 34424945)
Sci Immunol. 2022 Feb 18;7(68):eabn8014. (PMID: 35076258)
Infect Genet Evol. 2021 Oct;94:104998. (PMID: 34252616)
Mol Biol Evol. 2013 Apr;30(4):772-80. (PMID: 23329690)
Lancet Microbe. 2021 Jun;2(6):e240-e249. (PMID: 33778792)
Cell Rep Med. 2021 Jul 20;2(7):100354. (PMID: 34250512)
Int J Infect Dis. 2022 Jan;114:58-61. (PMID: 34757006)
Nat Med. 2022 Mar;28(3):496-503. (PMID: 35090165)
Cell. 2022 Apr 28;185(9):1588-1601.e14. (PMID: 35413241)
Ann Intern Med. 2022 May;175(5):674-681. (PMID: 35157493)
Science. 2020 Nov 13;370(6518):811-818. (PMID: 32958581)
Biomed Pharmacother. 2020 Oct;130:110629. (PMID: 33406577)
Diagn Microbiol Infect Dis. 2021 Dec;101(4):115516. (PMID: 34425504)
Int J Infect Dis. 2021 Sep;110:141-150. (PMID: 34273518)
Emerg Infect Dis. 2021;27(6):1737-1740. (PMID: 33871331)
Lancet Infect Dis. 2021 May;21(5):580-581. (PMID: 33545091)
Sci Rep. 2022 Jan 26;12(1):1438. (PMID: 35082344)
JCI Insight. 2020 Nov 19;5(22):. (PMID: 33035201)
Science. 2021 May 21;372(6544):815-821. (PMID: 33853970)
Res Sq. 2021 Jul 08;:. (PMID: 34268503)
J Clin Invest. 2022 May 2;132(9):. (PMID: 35259127)
Science. 2021 Jan 15;371(6526):288-292. (PMID: 33293339)
N Engl J Med. 2021 Dec 23;385(26):2487-2489. (PMID: 34818474)
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709. (PMID: 33400782)
Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089)
Lancet Infect Dis. 2022 Jun;22(6):744-745. (PMID: 35366960)
Mol Biol Evol. 2020 May 1;37(5):1530-1534. (PMID: 32011700)
Nat Med. 2021 Jul;27(7):1230-1238. (PMID: 34035535)
Lancet Glob Health. 2020 Nov;8(11):e1390-e1398. (PMID: 32979314)
BMC Infect Dis. 2022 Feb 5;22(1):127. (PMID: 35123418)
Science. 2021 Mar 25;:. (PMID: 33766944)
Nat Microbiol. 2020 Nov;5(11):1403-1407. (PMID: 32669681)
Nature. 2021 Dec;600(7889):530-535. (PMID: 34670266)
medRxiv. 2021 Nov 24;:. (PMID: 34845458)
Euro Surveill. 2020 Aug;25(32):. (PMID: 32794447)
- Subject Terms:
SARS-CoV-2 variants
- Publication Date:
Date Created: 20230505 Date Completed: 20230508 Latest Revision: 20231101
- Publication Date:
20231215
- Accession Number:
PMC10160723
- Accession Number:
10.1038/s41598-023-33443-1
- Accession Number:
37147348
No Comments.